GlassScriptPhysician profile
Jaclyn L Meis
NPI 1831685023
$13,563.77
in general payments reported to CMS, 2019-2025
79 companies · $2,454 in 2025
The $2,454 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,604 · 2022: $2,279 · 2023: $3,299 · 2024: $2,928 · 2025: $2,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,552 · Education: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,552.40 |
| Education | $1,128.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $884.70 | 2021-2025 | Tecvayli, Darzalex, Talvey |
| Merck Sharp & Dohme LLC | $776.32 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $769.27 | 2021-2025 | |
| Daiichi Sankyo INC. | $740.06 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Seagen INC. | $737.14 | 2021-2025 | Adcetris, Tukysa, Padcev |
| E.R. Squibb & Sons, L.L.C. | $699.80 | 2021-2025 | Opdivo, Opdualag, Reblozyl |
| Amgen INC. | $659.14 | 2021-2023 | Kyprolis, Lumakras, Xgeva |
| Incyte Corporation | $461.81 | 2021-2025 | Monjuvi, Jakafi, Pemazyre |
| Abbvie INC. | $402.32 | 2021-2025 | |
| Servier Pharmaceuticals LLC | $397.40 | 2021-2025 | |
| Pfizer INC. | $396.08 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $384.48 | 2021-2025 | Imfinzi, Enhertu, Calquence |
| Celgene Corporation | $379.03 | 2021-2024 | Pomalyst, Reblozyl |
| Myriad Genetic Laboratories, INC. | $346.11 | 2021-2023 | Mychoice Cdx, Precisetumor |
| Astellas Pharma US INC | $332.78 | 2021-2025 | Padcev, Xospata, Vyloy |
Show all 79 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $324.12 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $307.43 | 2021-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Genzyme Corporation | $296.65 | 2021-2025 | |
| Genentech USA, INC. | $273.01 | 2021-2025 | Gazyva, Lunsumio, Tecentriq |
| Gilead Sciences, INC. | $257.65 | 2021-2025 | Trodelvy |
| Sanofi-Aventis U.S. LLC | $239.99 | 2021-2024 | |
| Pharmaessentia USA Corporation | $226.87 | 2022-2025 | Besremi |
| Karyopharm Therapeutics INC. | $223.13 | 2021-2025 | Xpovio |
| Exelixis INC. | $208.10 | 2025 | Cabometyx |
| Lilly USA, LLC | $190.28 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Taiho Oncology, INC. | $162.17 | 2021-2025 | |
| Blueprint Medicines Corporation | $140.28 | 2021-2023 | Ayvakit |
| Boston Scientific Corporation | $127.43 | 2021-2025 | Spaceoar Vue System - 10ml |
| Recordati_rare_diseases_inc. | $111.74 | 2025 | Enjaymo |
| Coherus Oncology, INC. | $97.76 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $96.61 | 2023-2025 | Onivyde, Tazverik, Somatuline Depot |
| Stemline Therapeutics INC. | $95.88 | 2023-2025 | Orserdu |
| Agios Pharmaceuticals, INC. | $93.70 | 2021-2024 | Pyrukynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.19 | 2021-2023 | Gilotrif |
| Octapharma USA, INC. | $88.90 | 2023-2025 | Octagam Immune Globulin (Human), Panzyga |
| Aveo Pharmaceuticals, INC. | $86.86 | 2021-2025 | Fotivda |
| Puma Biotechnology, INC. | $84.36 | 2022-2025 | |
| Kite Pharma, INC. | $68.08 | 2021-2024 | Yescarta |
| Pharmacosmos Therapeutics INC. | $63.41 | 2024-2025 | Monoferric |
| Bayer Healthcare Pharmaceuticals INC. | $63.38 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $59.21 | 2021-2024 | |
| Tersera Therapeutics LLC | $57.87 | 2024 | Zoladex, Xermelo |
| Sobi, INC | $56.78 | 2022-2024 | |
| Genmab U.S., INC. | $54.81 | 2023-2024 | Epkinly |
| Glaxosmithkline, LLC. | $54.44 | 2021-2025 | Ojjaara |
| Pharmacyclics LLC, An Abbvie Company | $51.11 | 2021-2023 | Imbruvica |
| Myovant Sciences INC. | $50.44 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $50.30 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $45.62 | 2023-2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $41.12 | 2022-2025 | Ultomiris |
| Novocure INC. | $41.06 | 2021-2023 | Optune |
| Immunogen, INC. | $40.73 | 2023 | Elahere |
| G1 Therapeutics, INC. | $38.86 | 2022-2023 | Cosela |
| Amag Pharmaceuticals, INC. | $37.26 | 2021 | |
| Array Biopharma INC | $33.63 | 2021-2025 | Tukysa, Mektovi, Braftovi |
| Springworks Therapeutics, INC. | $33.06 | 2025 | Gomekli |
| Sumitomo Pharma America, INC. | $31.63 | 2023 | Orgovyx |
| Deciphera Pharmaceuticals INC. | $29.31 | 2025 | Qinlock |
| Emd Serono, INC. | $28.77 | 2023-2024 | Bavencio |
| Rigel Pharmaceuticals, INC. | $28.44 | 2023-2024 | Rezlidhia, Tavalisse |
| Cti Biopharma Corp. | $25.29 | 2022 | |
| Iovance Biotherapeutics, INC. | $24.57 | 2025 | Amtagvi |
| Kyowa Kirin, INC. | $23.50 | 2024 | Poteligeo |
| Organon LLC | $21.22 | 2022-2024 | |
| Adc Therapeutics America, INC. | $19.39 | 2023 | |
| Accord Healthcare, INC. | $19.29 | 2025 | |
| Janssen Scientific Affairs, LLC | $18.21 | 2022 | |
| Caris Mpi, INC. | $16.01 | 2025 | Mi Cancer Seek |
| Geron Corporation | $15.90 | 2025 | Rytelo |
| Adaptive Biotechnologies Corporation | $14.69 | 2024 | Clonoseq |
| Beone Medicines USA, INC. | $14.28 | 2025 | Brukinsa |
| Progenics Pharmaceuticals, INC. | $13.70 | 2025 | |
| Tg Therapeutics, INC. | $13.49 | 2021 | |
| Epizyme, INC. | $13.02 | 2022 | |
| Foundation Medicine, INC. | $12.54 | 2021 | |
| Eusa Pharma (US) LLC | $12.42 | 2022 | |
| Morphosys, US INC. | $12.21 | 2021 | |
| Dova Pharmaceuticals | $11.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.56 | 2021 |
Drugs and devices associated with these payments
Keytruda $496Tecvayli $295Darzalex $288Mychoice Cdx $288Enhertu $281Talvey $270Sarclisa $230Opdivo $228Besremi $196Pluvicto $154Imbruvica $153Venclexta $152Kisqali $147Lenvima $147Reblozyl $143Padcev $142Carvykti $142Epkinly $138Rybrevant $137Enjaymo $133Opdualag $130Tibsovo $130Adcetris $129Verzenio $124Jaypirca $124Fabhalta $118Xpovio $112Monjuvi $110Pomalyst $110Jakafi $109Lynparza $105Inqovi $98.33Lonsurf $98.33Orserdu $95.88Injectafer $95.85Pemazyre $94.47Scemblix $88.44Mekinist $83.87Xtandi $80.60Onivyde $79.85Gazyva $76.72Lunsumio $76.72Tecentriq $75.82Kyprolis $75.39Elrexfio $74.71Pyrukynd $74.67Elahere $73.42Elitek $69.99Inlyta $68.16Piqray $66.99Tukysa $66.11Talzenna $63.59Monoferric $63.41Voranigo $60.68Idhifa $57.93Lutathera $57.50Imfinzi $57.48Trodelvy $56.09Fotivda $55.94Welireg $54.78Calquence $52.29Fruzaqla $51.19Polivy $51.14Columvi $51.14Udenyca $50.37Vitrakvi $48.48Stivarga $48.48Libtayo $45.62Octagam Immune Globulin (Human) $44.89Orgovyx $44.07Panzyga $44.01Jevtana $43.96Lumakras $39.61Vectibix $39.52Xgeva $39.52Nplate $39.52Ibrance $37.54Alunbrig $36.03Odomzo $35.72Yonsa $35.72Zoladex $35.48Ninlaro $34.09Erleada $33.65Balversa $33.65Akeega $33.65Gomekli $33.06Zepzelca $32.98Blincyto $32.70Retevmo $32.50Bavencio $32.42Datroway $32.10Promacta $31.99Ayvakit $31.93Bosulif $31.87Tivdak $29.50Qinlock $29.31Yescarta $29.09Rezlidhia $28.44Tavalisse $28.44Vonjo $28.16
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaclyn Meis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.